Spotlight: Pharma R&D productivity is often framed as an execution problem: faster trials, lower development costs, better probability of success. But there is another source of value that receives less attention: how early portfolio decisions are made.
When the evidence around a program changes, the cost of waiting is not limited to additional development spend. Capital remains committed, scarce capabilities stay allocated, and potentially higher-value opportunities wait for resources.
The more important portfolio question may therefore be: “Is this still the best use of our next dollar of R&D investment?”
In my blogpost- Are We Making Pharma R&D Portfolio Decisions Early Enough? I explore the hidden economics of portfolio discipline—and why the speed at which organizations learn, decide and reallocate capital may be an important driver of R&D returns.
Checkout the full post below...
When the evidence around a program changes, the cost of waiting is not limited to additional development spend. Capital remains committed, scarce capabilities stay allocated, and potentially higher-value opportunities wait for resources.
The more important portfolio question may therefore be: “Is this still the best use of our next dollar of R&D investment?”
In my blogpost- Are We Making Pharma R&D Portfolio Decisions Early Enough? I explore the hidden economics of portfolio discipline—and why the speed at which organizations learn, decide and reallocate capital may be an important driver of R&D returns.
Checkout the full post below...
In pharma R&D, some of the most expensive decisions are not necessarily the wrong decisions. They are decisions made later than they could have been.
As portfolios grow and development programs become more complex, R&D productivity is often approached as an execution challenge: shorten timelines, improve trial performance, reduce development cost, increase probability of success.
All are important. But there is another lever that deserves more executive attention: the timing and quality of portfolio decisions.
When evidence changes the attractiveness of a program, continuing investment has a cost beyond the program's development spend. Capital remains committed. Scarce scientific and clinical capabilities stay allocated. Management attention remains absorbed. And potentially higher-value opportunities compete for those same resources.
The question for leadership, therefore, is not simply: “Is this program still viable?”
It is: “Is this still the best use of our next dollar of R&D investment?”
That shift changes the portfolio conversation.
Portfolio discipline is not simply about prioritizing assets once or twice a year. It requires a decision architecture that continually connects emerging evidence, probability of success, strategic fit, future investment, resource requirements, and expected value.
More importantly, the organization needs to be able to act when those signals change. The executive implication.
Improving R&D profitability may therefore require more than making individual programs faster or less expensive. It requires improving how quickly the portfolio learns, how clearly leadership sees the economic implications, and how decisively capital and resources can be reallocated.
That is where portfolio discipline becomes a source of competitive advantage. For R&D and enterprise leaders, I think there are three questions worth asking:
The answers may reveal as much about future R&D returns as the performance of the individual assets themselves. For leadership teams looking to improve R&D returns, this is an area worth examining closely: not only what is in the portfolio, but how the organization makes, revisits, and acts on investment decisions.
If this is on your leadership agenda, I’d welcome a conversation on where the biggest value opportunities may sit.
Are your portfolio governance processes helping you make investment decisions early enough? Let’s discuss where stronger decision discipline and faster capital reallocation could unlock value across your R&D portfolio.
As portfolios grow and development programs become more complex, R&D productivity is often approached as an execution challenge: shorten timelines, improve trial performance, reduce development cost, increase probability of success.
All are important. But there is another lever that deserves more executive attention: the timing and quality of portfolio decisions.
When evidence changes the attractiveness of a program, continuing investment has a cost beyond the program's development spend. Capital remains committed. Scarce scientific and clinical capabilities stay allocated. Management attention remains absorbed. And potentially higher-value opportunities compete for those same resources.
The question for leadership, therefore, is not simply: “Is this program still viable?”
It is: “Is this still the best use of our next dollar of R&D investment?”
That shift changes the portfolio conversation.
Portfolio discipline is not simply about prioritizing assets once or twice a year. It requires a decision architecture that continually connects emerging evidence, probability of success, strategic fit, future investment, resource requirements, and expected value.
More importantly, the organization needs to be able to act when those signals change. The executive implication.
Improving R&D profitability may therefore require more than making individual programs faster or less expensive. It requires improving how quickly the portfolio learns, how clearly leadership sees the economic implications, and how decisively capital and resources can be reallocated.
That is where portfolio discipline becomes a source of competitive advantage. For R&D and enterprise leaders, I think there are three questions worth asking:
- Are we generating the evidence needed to make investment decisions early enough?
- Do our governance processes surface changes in portfolio economics—or primarily track execution?
- And when the evidence changes, how quickly can we actually redeploy capital and capacity?
The answers may reveal as much about future R&D returns as the performance of the individual assets themselves. For leadership teams looking to improve R&D returns, this is an area worth examining closely: not only what is in the portfolio, but how the organization makes, revisits, and acts on investment decisions.
If this is on your leadership agenda, I’d welcome a conversation on where the biggest value opportunities may sit.
Are your portfolio governance processes helping you make investment decisions early enough? Let’s discuss where stronger decision discipline and faster capital reallocation could unlock value across your R&D portfolio.
Disclaimer: This article reflects observed industry trends and professional perspectives and does not constitute regulatory, legal, or operational advice. Read full disclaimer here.
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #RDStrategy #PortfolioStrategy #RDProductivity #DrugDevelopment #CapitalAllocation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
About the author:
Dr. Shruti Bhat is an Advisor in Operational Excellence and Business Continuity Across Pharma and MedTech Value Chains (end-to-end).
Keywords and Tags:
#Pharma #RDStrategy #PortfolioStrategy #RDProductivity #DrugDevelopment #CapitalAllocation #LifeSciences
Categories: Operational Excellence | Life Science Industry | Pharma R&D
Follow Shruti on YouTube, LinkedIn
Subscribe to Operational Excellence Academy YouTube channel: |  |
